Cargando…
Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
An available supply of intravenous immunoglobulin (IVIG) is essential for individuals with primary humoral immunodeficiency. A shortage in 1997 prompted the Food and Drug Administration (FDA) to revise guidelines for the licensure, production, and distribution of new IVIG products, including the sta...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501191/ https://www.ncbi.nlm.nih.gov/pubmed/22968971 http://dx.doi.org/10.1007/s15010-012-0323-9 |